BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 19997099)

  • 1. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses.
    Liu WM; Fowler DW; Smith P; Dalgleish AG
    Br J Cancer; 2010 Jan; 102(1):115-23. PubMed ID: 19997099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro.
    Correale P; Cusi MG; Del Vecchio MT; Aquino A; Prete SP; Tsang KY; Micheli L; Nencini C; La Placa M; Montagnani F; Terrosi C; Caraglia M; Formica V; Giorgi G; Bonmassar E; Francini G
    J Immunol; 2005 Jul; 175(2):820-8. PubMed ID: 16002679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supernatants from lymphocytes stimulated with Bacillus Calmette-Guerin can modify the antigenicity of tumours and stimulate allogeneic T-cell responses.
    Liu WM; Fowler DW; Gravett AM; Smith P; Dalgleish AG
    Br J Cancer; 2011 Aug; 105(5):687-93. PubMed ID: 21829193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.
    Smith PL; Yogaratnam Y; Samad M; Kasow S; Dalgleish AG
    Clin Transl Oncol; 2021 Jan; 23(1):110-121. PubMed ID: 32661823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells.
    Dauer M; Herten J; Bauer C; Renner F; Schad K; Schnurr M; Endres S; Eigler A
    J Immunother; 2005; 28(4):332-42. PubMed ID: 16000951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
    Correale P; Del Vecchio MT; La Placa M; Montagnani F; Di Genova G; Savellini GG; Terrosi C; Mannucci S; Giorgi G; Francini G; Cusi MG
    J Immunother; 2008; 31(2):132-47. PubMed ID: 18481383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.
    Lesterhuis WJ; de Vries IJ; Aarntzen EA; de Boer A; Scharenborg NM; van de Rakt M; van Spronsen DJ; Preijers FW; Figdor CG; Adema GJ; Punt CJ
    Br J Cancer; 2010 Oct; 103(9):1415-21. PubMed ID: 20924373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells.
    Kaneno R; Shurin GV; Kaneno FM; Naiditch H; Luo J; Shurin MR
    Cell Oncol (Dordr); 2011 Apr; 34(2):97-106. PubMed ID: 21290210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.
    Shalapour S; Font-Burgada J; Di Caro G; Zhong Z; Sanchez-Lopez E; Dhar D; Willimsky G; Ammirante M; Strasner A; Hansel DE; Jamieson C; Kane CJ; Klatte T; Birner P; Kenner L; Karin M
    Nature; 2015 May; 521(7550):94-8. PubMed ID: 25924065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice.
    Gou HF; Huang J; Shi HS; Chen XC; Wang YS
    PLoS One; 2014; 9(1):e85789. PubMed ID: 24465710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.
    Correale P; Botta C; Cusi MG; Del Vecchio MT; De Santi MM; Gori Savellini G; Bestoso E; Apollinari S; Mannucci S; Marra M; Abbruzzese A; Aquino A; Turriziani M; Bonmassar L; Caraglia M; Tagliaferri P
    Int J Cancer; 2012 Apr; 130(7):1577-89. PubMed ID: 21618510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells.
    Fang H; Ang B; Xu X; Huang X; Wu Y; Sun Y; Wang W; Li N; Cao X; Wan T
    Cell Mol Immunol; 2014 Mar; 11(2):150-9. PubMed ID: 24362470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells.
    Pei Q; Pan J; Zhu H; Ding X; Liu W; Lv Y; Zou X; Luo H
    Int Immunopharmacol; 2014 Mar; 19(1):10-6. PubMed ID: 24389382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The anti-tumor efforts of thymosin alpha1 on tumor lysate-pulsed dendritic cells in colon cancer in vitro and in vivo].
    Ma YL; Zheng Z; Li BD; Xie SJ; Li GX; Yan QH; Cai JH
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Nov; 23(11):1046-9. PubMed ID: 17988589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
    Correale P; Cusi MG; Tsang KY; Del Vecchio MT; Marsili S; Placa ML; Intrivici C; Aquino A; Micheli L; Nencini C; Ferrari F; Giorgi G; Bonmassar E; Francini G
    J Clin Oncol; 2005 Dec; 23(35):8950-8. PubMed ID: 16061910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses.
    Li H; Shao S; Cai J; Burner D; Lu L; Chen Q; Minev B; Ma W
    Immunology; 2017 Nov; 152(3):462-471. PubMed ID: 28664991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of murine tumour growth through CD8
    Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
    Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
    Bauer C; Bauernfeind F; Sterzik A; Orban M; Schnurr M; Lehr HA; Endres S; Eigler A; Dauer M
    Gut; 2007 Sep; 56(9):1275-82. PubMed ID: 17395611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine enhances cytotoxic activity of effector T-lymphocytes against chemo-resistant cholangiocarcinoma cells.
    Sawasdee N; Thepmalee C; Sujjitjoon J; Yongpitakwattana P; Junking M; Poungvarin N; Yenchitsomanus PT; Panya A
    Int Immunopharmacol; 2020 Jan; 78():106006. PubMed ID: 31780372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.